文献速递前列腺癌

根治性前列腺切除及盆腔淋巴结清扫后淋巴结阳性前列腺癌患者的管理:系统综述

Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review.
PubMed 文献 · Eur Urol Oncol · 2020-09-12

十年无生化复发生存率28%-56%,癌症特异性生存率72%-98%。低疾病负荷患者可初始观察、复发时 salvage 治疗;局部晚期且阳性淋巴结较多者辅助放疗±ADT可能改善生存。

要点

  • pN1患者十年无生化复发生存率28%-56%,但部分患者长期无病生存。
  • 低疾病负荷者可初始观察,复发时再行挽救治疗。
  • 局部晚期且阳性淋巴结较多者,辅助放疗±ADT可能改善生存。

核心结论

  • 多数pN1患者术后会出现生化复发,但部分选择患者可获长期无病生存。
  • 术后管理选项包括观察、辅助放疗和/或辅助ADT,应根据疾病特征个体化选择。

主要发现

  • 十年无生化复发生存率28%-56%,无临床复发生存率70%-92%,癌症特异性生存率72%-98%,总生存率60%-87.6%。
  • 分别有7项、5项和6项研究评估了观察、辅助放疗或辅助ADT的肿瘤学结局。
  • 低疾病负荷患者初始观察后复发时行挽救治疗是安全选择。
  • 局部晚期且阳性淋巴结较多者,辅助放疗±ADT可能改善生存。

关键数值与推荐

  • 风险分层依据病理Gleason评分、阳性淋巴结数量、病理分期和手术切缘状态。

临床怎么用

  • 根据病理Gleason评分、阳性淋巴结数量、病理分期和切缘状态进行风险分层,选择观察或辅助放疗和/或ADT。
  • 低疾病负荷患者可考虑初始观察,复发时再行挽救治疗。
  • 局部晚期且阳性淋巴结较多者考虑辅助放疗±ADT。

局限性

  • 纳入研究均为回顾性设计。
  • 缺乏不良事件数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Optimal management of prostate cancer (PCa) patients with lymph node invasion at radical prostatectomy and pelvic lymph node dissection still remains unclear. OBJECTIVE: To assess the effectiveness of postoperative treatment strategies for pathologically node-positive PCa patients. The secondary aim was to identify the most relevant prognostic factors to guide the management of pN1 patients. EVIDENCE ACQUISITION: A systematic review was performed in January 2020 using Medline, Embase, and other databases. A total of 5063 articles were screened, and 26 studies including 12 537 men were selected for data synthesis and included in the current review according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) recommendations. EVIDENCE SYNTHESIS: Ten-year biochemical recurrence (BCR)-free, clinical recurrence-free, cancer-specific (CSS), and overall (OS) survival rates ranged from 28% to 56%, 70% to 92%, 72% to 98%, and 60% to 87.6%, respectively. A total of seven, five, and six studies assessed the oncological outcomes of observation, adjuvant radiotherapy (aRT), or adjuvant androgen deprivation therapy (ADT), respectively. Initial observation followed by salvage therapies at the time of recurrence represents a safe option in selected patients with a low disease burden. The use of aRT with or without ADT might improve survival in men with locally advanced disease and a higher number of positive nodes. Risk stratification according to pathological Gleason score, number of positive nodes, pathological stage, and surgical margins status is the key to risk stratification and selection of the optimal postoperative therapy. Limitations of this systematic review are the retrospective design of the studies included and the lack of data on adverse events. CONCLUSIONS: While the majority of men with pN1 disease would experience BCR after surgery, long-term disease-free survival has been reported in selected patients. Management options to improve oncological outcomes include observation versus adjuvant therapies such as aRT and/or ADT. Disease characteristics should be used to select the optimal postoperative management for pN1 PCa patients. PATIENT SUMMARY: Finding node-positive prostate cancer after a radical prostatectomy often leads to high postoperative prostate-specific antigen levels and is overall a poor prognostic factor. However, this does not necessarily translate into poor survival for all men. Management can be tailored to the severity of disease and options include observation, androgen deprivation therapy, and/or radiotherapy.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Marra G, Valerio M, Heidegger I, et al. Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review. Eur Urol Oncol. 2020. PMID: 32933887. doi:10.1016/j.euo.2020.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。